London South East were delighted to welcome Incanthera to our April Investor Webinar last night (6.04.2021), where Chairman Tim McCarthy and CEO Dr Simon Ward presented and took questions.
Incanthera are an AQSE-listed oncology and dermatology therapy business with close ties to the University of Bradford cancer therapy labs. They develop and licence innovative technologies for the treatment of cancer and skin cancer.
They recently raised 1.14M from an oversubscribed share placing which is intended to see them through lucrative commercial negotiations with two global cosmetic companies as they agree licensing arrangements for their innovative anti-skin cancer cream Sol.
By quickly commercialising Sol, they hope to create a regular revenue stream to develop the business as they work on a significant pipeline of other cancer treatments.
The licensing revenues for Sol may be as much as £10M per annum - for a company which currently has a market capitalisation of around £10M, so this is a significant tipping point in the growth of the business.
Incanthera Plc (INC.PL)